BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32858764)

  • 1. IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signalling.
    Carr M; Mamand S; Chapman KL; Perrior T; Wagner SD
    J Cell Mol Med; 2020 Oct; 24(19):11573-11582. PubMed ID: 32858764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of TBK1 and IKKε, the non-canonical IκB kinases, as crucial pro-survival factors in HTLV-1-transformed T lymphocytes.
    Zhang H; Chen L; Cai SH; Cheng H
    Leuk Res; 2016 Jul; 46():37-44. PubMed ID: 27123832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
    Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
    Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3 activation pathways.
    Huang J; Liu T; Xu LG; Chen D; Zhai Z; Shu HB
    EMBO J; 2005 Dec; 24(23):4018-28. PubMed ID: 16281057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways.
    Möller M; Wasel J; Schmetzer J; Weiß U; Meissner M; Schiffmann S; Weigert A; Möser CV; Niederberger E
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.
    Clark K; Plater L; Peggie M; Cohen P
    J Biol Chem; 2009 May; 284(21):14136-46. PubMed ID: 19307177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription.
    Buss H; Dörrie A; Schmitz ML; Hoffmann E; Resch K; Kracht M
    J Biol Chem; 2004 Dec; 279(53):55633-43. PubMed ID: 15489227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells.
    Balka KR; Louis C; Saunders TL; Smith AM; Calleja DJ; D'Silva DB; Moghaddas F; Tailler M; Lawlor KE; Zhan Y; Burns CJ; Wicks IP; Miner JJ; Kile BT; Masters SL; De Nardo D
    Cell Rep; 2020 Apr; 31(1):107492. PubMed ID: 32268090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
    Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
    Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
    Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
    Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
    Zhou Z; Qi J; Lim CW; Kim JW; Kim B
    Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
    Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
    Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The non-canonical IκB kinases IKKε and TBK1 as potential targets for the development of novel therapeutic drugs.
    Niederberger E; Möser CV; Kynast KL; Geisslinger G
    Curr Mol Med; 2013 Aug; 13(7):1089-97. PubMed ID: 23157677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAVS activates TBK1 and IKKε through TRAFs in NEMO dependent and independent manner.
    Fang R; Jiang Q; Zhou X; Wang C; Guan Y; Tao J; Xi J; Feng JM; Jiang Z
    PLoS Pathog; 2017 Nov; 13(11):e1006720. PubMed ID: 29125880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity.
    tenOever BR; Sharma S; Zou W; Sun Q; Grandvaux N; Julkunen I; Hemmi H; Yamamoto M; Akira S; Yeh WC; Lin R; Hiscott J
    J Virol; 2004 Oct; 78(19):10636-49. PubMed ID: 15367631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK epsilon.
    Harris J; Olière S; Sharma S; Sun Q; Lin R; Hiscott J; Grandvaux N
    J Immunol; 2006 Aug; 177(4):2527-35. PubMed ID: 16888014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IκB kinase ε (IKKε): a therapeutic target in inflammation and cancer.
    Verhelst K; Verstrepen L; Carpentier I; Beyaert R
    Biochem Pharmacol; 2013 Apr; 85(7):873-80. PubMed ID: 23333767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDX19 Inhibits Type I Interferon Production by Disrupting TBK1-IKKε-IRF3 Interactions and Promoting TBK1 and IKKε Degradation.
    Zhang K; Zhang Y; Xue J; Meng Q; Liu H; Bi C; Li C; Hu L; Yu H; Xiong T; Yang Y; Cui S; Bu Z; He X; Li J; Huang L; Weng C
    Cell Rep; 2019 Jan; 26(5):1258-1272.e4. PubMed ID: 30699353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.